the manifestations of acute GVHD. In the original reports, all patients had rash as the cardinal sign of GVHD, and We have undertaken a formal study to evaluate the virtually all patients with severe cutaneous GVHD also had reproducibility of retrospective assessments for grading visceral involvement, but it is now clear that severe exfolithe severity of acute GVHD. Using criteria previously ative cutaneous GVHD can occur in the absence of gut or established by the Seattle group, three reviewers indeliver disease and that active visceral GVHD can occur in pendently assigned GVHD severity grades for a set of the absence of cutaneous disease. 2,3 Severe diarrhea is less 100 marrow transplant patients. Significant differences common as a manifestation of GVHD than it used to be, were found in the distribution of GVHD grades assigned perhaps because current prophylactic regimens are more by one of the reviewers as compared to the other two effective than those used 20-25 years ago. 3 Nausea, anorreviewers. In only 40% of cases did all three reviewers exia and vomiting were not explicitly considered in the assign the same GVHD grade, and in only 68-71% of original criteria, but with the increasing use of endoscopic cases did all three reviewers assign the same grade biopsies for diagnosis, these symptoms are now recognized within 0-I vs II-IV or 0-II vs III-IV categories. Despite as manifestations of acute GVHD. 4 Furthermore, the origthe high rate of disagreement between any two inal criteria were developed before veno-occlusive disease, reviewers, at least two reviewers assigned the same viral enteritis and C. difficile enteritis were recognized as overall GVHD grade in 93% of cases. These results sugfrequent complications of marrow transplantation. 3 Intergest that current criteria for assessing the severity of actions between GVHD and other concomitant compli-GVHD by a single reviewer are not sufficiently reliable cations have not been well studied, 5 although guidelines for for rigorous clinical studies. As an alternative to the grading GVHD in such situations have been proposed.
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original criteria, we have developed and tested simpliResults of an earlier study showed considerable diversity fied criteria that summarize the clinical course of among different reviewers in grading acute GHVD. 7 In that GVHD as reflected by the progression of disease and study, a brief clinical vignette was reviewed by 48 transthe amount of immunosuppressive treatment used to plant physicians worldwide, and the concordance rate for control the disease. Our results suggest that the revised grading GVHD was only 55%. Concordance rates were criteria might yield more reproducible retrospective similarly low with other vignettes designed to test the diaggrading than the original criteria. Although the original nosis of acute GVHD and decisions to treat acute GVHD. criteria and the revised criteria might produce different Although revisions of the original criteria have been proresults for individual patients, the overall distributions posed, 8 no attempt has been made to validate the reproduciof grades with the two systems were similar. The probility of GVHD grading with primary case information. posed revised criteria could be implemented without In 1991, the task of assigning GVHD grades for patients disrupting the continuity and consistency with previous transplanted at our center was passed from one reviewer grading assigned by the original criteria.
to another. It soon became apparent that this change was Keywords: marrow transplantation; graft-versus-host accompanied by an increase in the overall grade of GVHD. disease Extensive review of patient selection and treatment regimens did not identify any factors convincingly associated with increased GVHD grades other than the change in Criteria originally proposed by the Seattle group 1 have been reviewers. We therefore undertook a formal study to assess widely used for grading the clinical severity of acute the reproducibility of grading according to the original cri-GVHD after allogeneic marrow transplantation. During the teria. Subsequently we developed revised and simplified past two decades, certain limitations of these criteria have grading criteria which have improved reproducibility as become apparent through the evolution in understanding compared to the original criteria.
Methods Statistics
Differences between reviewers were evaluated both by Reviewers paired Wilcoxon sign rank tests and unpaired MannReviewer A (Dr Sanders) was responsible for assigning Whitney U tests. The paired test evaluates differences at the GVHD grades before 1991, and reviewer B (Dr Martin) level of individual patients, and the unpaired test provides assumed this task in 1991. Reviewer C (Dr Nash) was information about overall differences in the distribution of recruited to participate in the study when differences in grades given by two reviewers. Agreement between grading GVHD by reviewers A and B became apparent.
reviewers 
Results

Patients
A cohort of 100 patients who received marrow from an
Comparison of GVHD grades assigned by three different HLA-identical sibling with the use of methotrexate and reviewers using the original Seattle criteria cyclosporine for GVHD prophylaxis was selected to span
We compared GVHD grades independently assigned by the change of reviewers in 1991. Reviewer B assigned three different reviewers who each evaluated the same set GVHD grades for the last 45 patients who had originally of 100 marrow transplant recipients according to the origbeen given GVHD grades by reviewer A, and reviewer A inal Seattle criteria (Table 1 ). The distributions of overall in turn assigned GVHD grades for the first 55 patients grades and skin and liver stages assigned by reviewers A originally given GVHD grades by reviewer B. Reviewer C subsequently assigned GVHD grades for all 100 patients previously given grades by reviewers A and B. All three serum bilirubin concentration.
and C were closely similar, although reviewer C tended to biopsy was obtained (Table 3 ). More than half of these patients had evidence of veno-occlusive disease, and most assign lower stages of gut severity than reviewer A. Reviewer B assigned higher overall grades and higher skin had diarrhea with peak volumes Ͼ500 ml/day. Although the medical summary acknowledged GVHD as a possible and liver stages than reviewers A and C. In assessing gut GVHD, reviewers B and C showed the most disparate diagnosis in 12 of the 19 cases, only one of these patients received any treatment for GVHD, and abnormalities that results. By unpaired rank sum tests, differences in the distribution of overall grades assigned by reviewer B and the could have been caused by GVHD resolved without treatment in the others. other two reviewers reached statistical significance (P = 0.04). Such differences could therefore affect the Among seven cases where reviewer B assigned overall grade III GVHD and reviewer A or C assigned grade 0-II interpretation of study results.
In only 40% of cases did all three reviewers assign the GVHD, five had rash, and skin biopsy was positive in all six cases where a skin biopsy was obtained. Most of these same GVHD grade, and in only 68-71% of cases did all three reviewers assign the same grade within 0-I vs II-IV patients had evidence of veno-occlusive disease, and most had diarrhea with peak volumes Ͼ500 ml/day. Although or 0-II vs III-IV categories (Table 2) . Agreement rates were similar for assignment of skin, liver and gut stages, the medical summary acknowledged GVHD as a possible diagnosis in six of the seven cases, only three of these indicating that differences in overall grading did not result predominantly from disagreement in the staging of one patients received any treatment for GVHD. The lack of treatment and the correspondingly lower grading by particular organ. Agreement rates for overall grades assigned by reviewers A and C were not significantly better reviewers A and C among the 26 cases taken together appear to reflect the judgment that abnormalities in the liver than those between reviewers A and B or between reviewers B and C (P у 0.32). Even though the average and gut were caused predominantly by complications other than GVHD. Atypical time of onset after transplant, gradual grades and stages assigned by reviewers A and C were closely similar, these two reviewers disagreed with each onset or brief duration of abnormalities could have been additional factors influencing decisions not to administer other in assigning overall grades for individual patients just as much as they disagreed with reviewer B. Values for immunosuppressive treatment by the attending physician and leading to lower staging and grading by reviewers A kappa statistics ranged from 0.36 ('fair') to 0.44 ('moderate'), indicating that agreement in assigning overall and C. grades is less than adequate. Despite the high rates of disagreement between any two reviewers, at least two Development and testing of revised criteria for GVHD reviewers assigned the same overall GVHD grade in 93 grading cases, and in only seven of the 100 cases did all three reviewers assign different grades (data not shown).
The cases summarized in Table 3 illustrate some of the difficulties that can be encountered when the original Seattle criteria are used for grading GVHD. In an attempt to Reasons for differences in grading address these difficulties, we developed simplified grading criteria that primarily reflect the degree of difficulty in conIndividual cases were reviewed in order to determine trolling GVHD after it has occurred (Table 4 without characteristics that could have led to higher grading and italics). Whereas the original criteria emphasize peak severstaging by reviewer B as compared to reviewers A and C. ity of abnormalities in the skin, liver and gut, the revised In 19 cases, reviewer B assigned overall grade II GVHD and reviewer A or C assigned grade 0-I GVHD. All 19 had rash, often involving у50% of the body surface, and Table 3 Characteristics of cases where reviewer B assigned a higher overall grade than reviewer A or C skin biopsy was positive in eight of 12 cases where a skin 1 were used to assign GVHD organ stages and Seattle criteria 1 were used for grading. b Patients in this group were categorized as having grade III GVHD by overall peak severity grades for 100 marrow transplant recipients. Differences in two-way agreement rates between reviewers A and B, A and C, reviewer B and grades 0-II GVHD by reviewer A or C when original Seattle criteria 1 were used for grading. and B and C are not statistically significant.
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Table 4
Revised criteria proposed for grading acute GVHD patients, reviewer B assigned higher overall grades than reviewer C when the original criteria were used (P Ͻ 0.001
Grade Criteria a by paired rank sum test, and P = 0.03 by unpaired rank sum test) ( applied to the first set of 100 patients (P = 0.0002) III Clinical presentation as described for grade II but without ( improved with the revised criteria applied to the second 100 patients (82%) as compared to the original criteria a Expanded criteria are given in italics.
applied to the first 100 patients (79%) ( Table 6 ). Discrepant cases were reviewed, and a consensus grading for each patient was developed with implementation of additional criteria emphasize overall time course and response to pricriteria for grading (Table 4 with italics). The expanded crimary therapy. In addition, the revised criteria do not include teria specified that any immunosuppressive treatment a grade I category, primarily because this category is almost initiated before day 100 and not administered as part of a always incorporated with grade 0 GVHD in retrospective protocol for treatment of chronic GVHD would be conclinical studies.
sidered as treatment of acute GVHD. Patients who died In order to evaluate the reproducibility of the revised within 2-3 weeks after starting treatment would be categorsystem for assessing GVHD, reviewers B and C indepenized as having grade II GVHD if manifestations of GVHD dently assigned GVHD grades for another set of 100
showed improvement in at least one organ without deteriopatients who had received an allogeneic marrow transplant ration in others before death. Patients who died within 2-from either a related or an unrelated donor (Table 5) . With 3 weeks after starting treatment would be categorized as categories of 0-I, II, III and IV applied to the first 100 having grade III GVHD if manifestations of GVHD showed no improvement before death. Patients who had mild and transient recurrent manifestations of GVHD without a secondary treatment given 'prematurely' or who had secondary therapy given as a result of very rapid glucocort- 
B (R1) C (R1) B/C (R2) A (R2) B (O)
0 2 1 1 8 1 9 2 6 2 1
B-C (1) P value B-C (2) P value B/C-A (2)
Reviewers B and C made independent assessments using revised criteria (Table 4 without (Table 4 with italics) and represents results from Table 5 . P values reflect differences between successive columns. not statistically significant. icoid taper (eg Ͼ0.2 mg/kg prednisone at intervals Ͻ5 Discussion days) or as a result of inadequate primary therapy, those who had secondary treatment solely as a consequence of Results of this study show appreciable disagreement between independent reviewers in assigning acute GVHD unsuccessful local treatment with agents such as oral beclomethasone or psoralen and ultraviolet A irradiation without grades by the original Seattle criteria. Variation between reviewers can produce differences in the assessment of systemic glucocorticoids, and those who received secondary immunosuppressive treatment despite a negative biospy GVHD not only for individual patients but also for populations of patients. These results suggest that current of the relevant organ would not be categorized as having grade III GVHD. Any increase in glucocorticoid doses methods for assessing the severity of GVHD by a single reviewer are not sufficiently reliable for rigorous clinical initiated because of recurrent symptoms during an appropriately paced taper schedule would be considered as secondstudies. Better methods for grading GVHD will be needed in studies where the severity of GVHD represents the ary therapy. Patients who died with infection as the primary cause of death in the setting of ongoing GVHD manifesprimary endpoint for comparing two groups of patients or in studies where the severity of GVHD is correlated with tations and continued immunosuppressive treatment would be categorized as having grade IV GVHD. Grade IV specific risk factors. Several approaches could be developed to improve the GVHD would not be assigned if another overwhelming problem such as veno-occlusive disease was considered to reliability of GVHD grading. Much of the difficulty in grading GVHD results from the ambiguity of clinical manibe the primary cause of death.
In order to evaluate the reproducibility of the revised festations and the lack of objective criteria for distinguishing abnormalities caused by GVHD from those system with expanded criteria for assessing GVHD, reviewer A independently assigned GVHD grades for the caused by other complications. In randomized prospective studies where risk factors for complications other than second set of 100 patients previously categorized by reviewers B and C. In comparing the consensus grading by GVHD are balanced between groups, abnormalities can be assessed and compared between groups without attempting reviewers B and C with the grades assigned by reviewer A, the paired test showed a statistically significant difference to determine the exact cause. The distinction between GVHD and other complications involving the skin, liver (P = 0.01), but the unpaired test did not (P = 0.37) ( Table 5 ). Before the expanded criteria were established, and gut can be ignored, thereby avoiding bias in the attribution of etiology before treatment and in the interpretation there was 82% agreement between reviewers B and C in assigning grades 0-II vs III-IV GVHD. With the expanded of results after treatment. This agnostic approach cannot be applied in studies where the distinction between GVHD and criteria, there was 94% agreement between reviewer A and the B/C consensus in assigning grades within the same catother complications is necessary or in clinical trials where risk factors for complications other than GVHD are not balegories (P = 0.009) ( Table 6 ). The overall agreement within categories of 0, II, III and IV was not improved, however, anced between groups. In this situation, the reliability of GVHD grading might best be improved by using a panel of because the agreement in assigning grades 0 vs II-IV decreased from 97% for reviewers B and C to 89% for independent reviewers to determine a median or consensus grade. In the present study, two-or three-way agreement reviewer A and the B/C consensus (P = 0.03) ( Table 6 ). In nine of the 11 discrepant grade 0 vs II-IV cases, reviewer among the three reviewers occurred in 93% of cases, and three-way disagreement occurred in only 7% of cases. A assigned grade 0 when the B/C consensus assigned grade II. In one case, primary treatment for upper tract gastroReliability and reproducibility of grading might also be improved by more explicit elaboration of rules and guideintestinal GVHD was started on day 90 after transplantation. In three cases, GVHD was diagnosed at autopsy, but lines for assessment of GVHD, but the complexity of clinical variation might make this task extremely difficult. treatment had not been given because abnormalities had been attributed primarily to causes other than GVHD. In
As an alternative approach for improving the reliability of GVHD grading, we developed and tested simplified crifour cases, skin biopsy was diagnostic of GVHD, but symptoms were not sufficiently severe to warrant systemic treatteria that summarize the clinical course as reflected by the progression of disease and the amount of immunosuppresment. In one case, nausea and rash were attributed to GVHD, but no treatment was given, and symptoms sive treatment used to control the disease. The initial test of these proposed criteria greatly improved the degree of resolved spontaneously. In retrospect, reviewer A had not realized that according to the revised criteria, the occuragreement in distinguishing patients with GVHD from those who did not have GVHD. We found, however, that rence of characteristic abnormalities together with histologic confirmation was sufficient for assignment of grade reproducible discrimination between grades II, III and IV GVHD required further elaboration of rules for categoriz-II GVHD even when no treatment was given.
In order to determine whether the distribution of GVHD ation. In particular, we found it necessary to clarify the rules for categorization in situations where the clinical mangrades at this center would be affected by implementing new criteria for categorization, we compared the consensus agement decisions for individual patients might not accurately reflect the severity of GVHD. Application of this grading developed by reviewers B and C with results of grading previously assigned by reviewer B according to the approach for GVHD grading to a larger population of patients might identify additional situations where further original criteria (Table 5 ). There was no significant difference in the distribution of GVHD grades assigned by these elaboration of rules for categorization will be necessary in order to assure accuracy and reproducibility. Based on the two methods (P = 0.78 by the paired test, and P = 0.99 by the unpaired test).
level of agreement in discriminating between grades 0 and II-IV assigned by reviewers B and C and the level of agreecauses of abnormal organ function should be excluded by appropriate tests. ment in discriminating between grades 0-II and III-IV Previous studies have shown increasing risks of transassigned by reviewer A and the consensus grades assigned plant-related mortality associated with higher grades of by reviewers B and C, we are confident that highly repro-GVHD. 11 Attempts have been made to improve the utility ducible results in GVHD grading can be achieved with the of GVHD grading as a prognostic tool by rearranging organ revised criteria. stages in ways that reproducibly strengthen the association The revised system for grading relies heavily on the between overall grade and risk of transplant-related morclinical judgement and treatment decisions of physicians tality. 8 The rearranged criteria still depend on assessments responsible for the care of patients. To a considerable of the peak severity of abnormalities in the skin, liver and extent, the revised grading system represents a categorizgut which have been shown to lack reproducibility. Moreation of clinical management, and the accuracy of grading over, the rearranged criteria do not incorporate information could suffer if manifestations of GVHD are not recognized concerning the timing or duration of abnormalities. For and reported or if treatment decisions are made these reasons, this GVHD grading system is likely to be of capriciously. From reviewing records in our own center, it limited utility for prognostic purposes when applied to speis apparent that GVHD is not managed in an entirely concific patients at specific times after transplantation when the sistent manner among different physicians, and we suspect peak severity of GVHD manifestations is still unknown. By that variation between centers might be greater than the definition with both the original Seattle criteria and with variation within centers. Grading according to the revised the proposed revised criteria, grade IV GVHD is strongly criteria might be especially difficult in centers where highassociated with a high risk of transplant-related mortality. dose glucocorticoids are used for prophylaxis and in centers With the limited numbers of patients evaluated by the where standardized treatment regimens and taper schedules revised criteria, we have not yet accrued enough data to have not been developed. In these situations, clinical assess associations between transplant-related mortality and grading by the revised criteria requires unambiguous grades 0, II and III GVHD. documentation of the rationale for all changes in immunoFor retrospective studies, GVHD grading serves primsuppressive treatment.
arily as a code that concisely summarizes the clinical Clinical grading of acute GVHD has long been used not impact of GVHD after transplantation. Although the orionly as a tool for retrospective evaluation after transplanginal Seattle criteria and the revised criteria for grading tation but also for making decisions concerning the need GVHD might produce different results for individual for treatment.
10 Although treatment protocols often specify patients, the similarity in overall results with the two sys-'grade II' GVHD as an indication for treatment, clinical tems was reassuring. Our results suggest that the revised management decisions actually entail evaluation of many criteria could be implemented without disrupting the contifactors in addition to overall severity. The need for treatnuity and consistency with previous grading assigned by ment is often urgent when adequate GVHD prophylaxis the original Seattle criteria. For the purposes of retrospeccannot be given because of toxicity or contraindication, tive studies, the proposed revised criteria offer the advanwhen the recipient has HLA disparity with the donor, when tage of possibly improved reproducibility as compared to GVHD occurs early after transplantation, when fever the original criteria. Further testing of the revised criteria occurs as a manifestation of 'hyperacute' GVHD, or when by reviewers who did not participate in their development manifestations of GVHD show rapid progression from day will be necessary before they can be considered for adopto day. When these risk factors are absent, treatment can tion as a standard. often be deferred, even in patients with grade III GVHD according to the original Seattle criteria (eg nonprogressive rash involving Ͻ50% of the body surface with serum biliru
